8-20-04



**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Luigi Grasso, et al.

Confirmation No.: 9935

**Application No.: 10/624,631** 

Group Art Unit: 1645

Filing Date: July 21, 2003

**Examiner: Not Yet Assigned** 

METHODS FOR GENERATING ENHANCED ANTIBODY-PRODUCING

CELL LINES WITH IMPROVED GROWTH CHARACTERISTICS

EXPRESS MAIL LABEL NO: EL999288134US
DATE OF DEPOSIT: Cargues 19, 2001

CUPELBB599

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

 $\boxtimes$ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or

	before the mailing date of a first Office Action after the filing of reques					
	continued examination under § 1.114, no additional fee is required.					
	In accordance with § 1.129(a), this In	In accordance with § 1.129(a), this Information Disclosure Statement is being				
	filed in connection with   the first	filed in connection with   the first or   second After Final Submission,				
	therefore:					
	Certification in Accordance with § 1.97(e) is attached; or					
	The fee of \$180.00 as set forth in § 1.17(p) is attached.					
	In accordance with § 1.97(c), this Inf	In accordance with § 1.97(c), this Information Disclosure Statement is being				
	(b) above but before the mailing date of					
	either a Final Action under § 1.113 or	a Notice of Allowance under § 1.311, or				
	prosecution in the application, therefore:					
	Certification in	Accordance with § 1.97(e) is attached;				
	or					
	The fee of <u>\$180</u>	.00 as set forth in § 1.17(p) is attached.				
	In accordance with § 1.97(d), this Information Disclosure Statement is being					
filed after the mailing date of either a Final Action under § 1.113						
	re, or simultaneously with, the payment					
	of the Issue Fee, therefore included a	are: Certification in Accordance with §				
	1.97(e); and the submission fee of \$18	0.00 as set forth in § 1.17(p).				
$\boxtimes$	Copies of each of the references liste	ed on the attached Form PTO-1449 are				
	enclosed herewith.					
	Copies of references listed on the a	attached Form PTO-1449 are enclosed				
	herewith					

DOCKET NO.: MOR-0241/HD0002US - 3 - PATENT						
	Copie	es of references listed on the attached Form PTO 1449 are n	ot required to			
	be sul	bmitted pursuant to the June 30, 2003 recent revisions	to 37 CFR §			
	1.98(a					
	EXCE					
		In view of the voluminous nature of references [list as	appropriate],			
		and the likelihood that these references are available to	the Examiner,			
		copies are not enclosed herewith.				
		In accordance with § 1.98(d), copies of the following ref	ferences listed			
		on the attached Form PTO-1449 are not enclosed here	ewith because			
		they were previously cited by or submitted to the U.S.	S. Patent and			
		Trademark Office in patent application(s) for which a claim	im for priority			
		under 35 U.S.C.§ 120 have been made in the instant appli	cation:			
		Copies of references [list as appropriate]	isted on the			
		attached Form PTO-1449 were previously cited by	y or submitted			
		to the Patent and Trademark Office in prior Ap	oplication No.			
		, filed .				
Pleas	e charge	e any deficiency or credit any overnayment to Denosit Ac	count No. 23-			

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Enclosed is a copy of the PCT International Search Report dated July 28, 2004 (number 103 on Form PTO-1449), which indicates the references considered to be relevant.

□ The relevance of those listed references which are not in the English language is as follows:
 □ There are no listed references which are not in the English language.
 □ Date: Appl (9 2004
 □ Vohn W Caldwell Registration No. 28,937

WOODCOCK WASHBURN LLP One Liberty Place - 46th Floor Philadelphia, PA 19103 Telephone: (215) 568-3100

DOCKET NO.: MOR-0241/HD0002US - 4 -

Facsimile: (215) 568-3439

© 2004 WW

**PATENT** 





	-1449 Modified t and Publications	Docket No. MOR-0241/ HD0002US	Application No. 10/624,631			
Cited b (Use several s	by Applicant sheets if necessary)	Applicant Luigi Grasso, et al.				
	nent of Commerce Frademark Office	Filing Date July 21, 2003	Group 1645			
		Confirmation No. 9935				
OTHE	R DOCUMENTS (Inch	uding Author, Title, Dat	e, Pertinent Pages, Etc.)			
103	Copy of the PCT Inter	national Search Report da	ated July 28, 2004 (PCT/US03/22743)			
104	Kim, N., et al., "The role of DNA repair in somatic hypermutation of immunoglobulin genes," J. Exp. Med., 1998, 187(11), 1729-1733					
105						
106						
107						
108	Winter, D.B., et al., "Altered spectra of hypermutation in DNA repair-deficient mice," <i>Phil. Trans. R. Soc. Lond. B</i> , <b>2001</b> , <i>356</i> , 5-11					
EXAMINER		DATE CO	ONSIDERED			





Form PT	Docket No. MOR-0241/ HD0002US	Application No. 10/624,631				
List of Pate Cited (Use severa	Applicant Luigi Grasso, et al.					
U.S. Department of Commerce Patent and Trademark Office			Filing Date July 21, 2003	Group 1645		
	Confirmation No. 9935					
	U. S	S. PATENT	T DOCUMENTS	•		
Examiner Initial	Document No.	Date	Name		Class	Subclass
108	2002/0055106 A1	05/09/02	Nicolaides, et al.		435	6
	FORE	IGN PATE	ENT DOCUMENTS			, mar.
Examiner Initial	Document No.	Date	Country		Translation YES NO	
Thirtial		Dutt	Country		1123	110
					<u> </u>	
EXAMINER			DATE CONSIDERED			